NCT05436275View on ClinicalTrials.gov

A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2024

Conditions
Chronic Rhinosinusitis With Nasal Polyposis
Interventions
BIOLOGICAL

CM310

300 mg every two weeks

BIOLOGICAL

Placebo

once every two weeks

Trial Locations (1)

Unknown

Beijing Tongren Hospital, CMU, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05436275 - A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2） | Biotech Hunter | Biotech Hunter